Rheumatic Heart Disease Is a Neglected Disease Relative to Its Burden Worldwide: Findings From Global Burden of Disease 2019.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
05 07 2022
Historique:
pubmed: 23 6 2022
medline: 26 7 2022
entrez: 22 6 2022
Statut: ppublish

Résumé

Background Rheumatic heart disease (RHD) takes a heavy toll in low- and middle-income countries. We aimed to present worldwide estimates for the burden of the RHD during 1990 to 2019 using the GBD (Global Burden of Disease) study. Methods and Results Sociodemographic index (SDI) and age-period-cohort analysis were used to assess inequity. The age-standardized death, disability-adjusted life years, incidence, and prevalence rates of RHD were 3.9 (95% uncertainty interval, 3.3-4.3), 132.9 (95% uncertainty interval, 115.0-150.3), 37.4 (28.6-46.7), and 513.7 (405.0-636.3) per 100 000 in 2019, respectively. The age-standardized incidence and prevalence rates increased by 14.4% and 13.8%, respectively. However, disability-adjusted life years and death rates decreased by 53.1% and 56.9%, respectively. South Asia superregion had the highest age-standardized disability-adjusted life years and deaths. Sub-Saharan Africa had the highest age-standardized incidence and prevalence rates. There was a steep decline in RHD burden among higher-SDI countries. However, only age-standardized deaths and disability-adjusted life years rates decreased in lower-SDI countries. The age-standardized years of life lost and years lived with disability rates for RHD significantly declined as countries' SDI increased. The coefficients of birth cohort effect on the incidence of RHD showed an increasing trend from 1960 to 1964 to 2015 to 2019; however, the birth cohort effect on deaths attributable to RHD showed unfailingly decreasing trends from 1910 to 1914 to 2015 to 2019. Conclusions There was a divergence in the burden of RHD among countries based on SDI levels, which calls for including RHD in global assistance and funding. Indeed, many countries are still dealing with an unfinished infectious disease agenda, and there is an urgency to act now to prevent an increase in future RHD burden.

Identifiants

pubmed: 35730651
doi: 10.1161/JAHA.122.025284
pmc: PMC9333364
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e025284

Références

PLoS Negl Trop Dis. 2015 Sep 15;9(9):e0004033
pubmed: 26371755
Eur Heart J. 2018 Dec 21;39(48):4233
pubmed: 30576471
PLoS Negl Trop Dis. 2021 Jan 14;15(1):e0008990
pubmed: 33444355
Lancet Glob Health. 2019 Oct;7(10):e1297-e1299
pubmed: 31537348
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33350929
BMC Public Health. 2016 Aug 27;16:897
pubmed: 27567604
Sci Rep. 2019 Nov 19;9(1):17022
pubmed: 31745178
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Nat Rev Dis Primers. 2016 Jan 14;2:15084
pubmed: 27188830
N Engl J Med. 2017 Aug 24;377(8):713-722
pubmed: 28834488
Front Immunol. 2019 Sep 13;10:2184
pubmed: 31572391
Front Surg. 2020 Aug 12;7:47
pubmed: 32903397
Lancet. 2019 May 11;393(10184):1984-2005
pubmed: 31043324
Med J Aust. 2020 Nov;213 Suppl 10:S3-S31
pubmed: 33190287
World Health Organ Tech Rep Ser. 1954 Apr;78:1-25
pubmed: 13157434
Lancet Glob Health. 2019 Oct;7(10):e1388-e1397
pubmed: 31537369
Lancet. 2012 Mar 10;379(9819):953-964
pubmed: 22405798
Cardiovasc J Afr. 2008 May-Jun;19(3):135-40
pubmed: 18568172
PLoS Negl Trop Dis. 2018 Jun 13;12(6):e0006577
pubmed: 29897915
Cancer Med. 2021 Apr;10(7):2496-2508
pubmed: 33665966
Heart Asia. 2015 Aug 19;7(2):7-11
pubmed: 27326214
Cardiovasc J Afr. 2015 Nov-Dec;26(6):251
pubmed: 26659439
Nat Rev Cardiol. 2013 May;10(5):284-92
pubmed: 23546444
J Am Heart Assoc. 2020 Apr 21;9(8):e014800
pubmed: 32308101
Lancet. 2018 Mar 10;391(10124):926
pubmed: 29536848
Ethn Dis. 2019 Feb 21;29(Suppl 1):159-172
pubmed: 30906165
N Engl J Med. 2007 Aug 2;357(5):439-41
pubmed: 17671252
Heart. 2005 Sep;91(9):1131-3
pubmed: 16103536
Lancet. 2022 Apr 23;399(10335):1625-1645
pubmed: 35397236

Auteurs

Seyyed-Hadi Ghamari (SH)

Non-Communicable Diseases Research Center Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.

Mohsen Abbasi-Kangevari (M)

Non-Communicable Diseases Research Center Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.

Sahar Saeedi Moghaddam (S)

Non-Communicable Diseases Research Center Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.

Arya Aminorroaya (A)

Non-Communicable Diseases Research Center Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.
Tehran Heart CenterTehran University of Medical Sciences Tehran Iran.

Negar Rezaei (N)

Non-Communicable Diseases Research Center Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.
Endocrinology and Metabolism Research Center Endocrinology and Metabolism Clinical Sciences Institute Tehran University of Medical Sciences Tehran Iran.

Parnian Shobeiri (P)

Non-Communicable Diseases Research Center Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.

Zahra Esfahani (Z)

Non-Communicable Diseases Research Center Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.
Department of Biostatistics University of Social Welfare and Rehabilitation Sciences Tehran Iran.

Mohammad-Reza Malekpour (MR)

Non-Communicable Diseases Research Center Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.

Nazila Rezaei (N)

Non-Communicable Diseases Research Center Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.

Ali Ghanbari (A)

Non-Communicable Diseases Research Center Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.

Mohammad Keykhaei (M)

Feinberg Cardiovascular and Renal Research Institute Northwestern University, School of Medicine Chicago IL.

Mohammadreza Naderian (M)

Non-Communicable Diseases Research Center Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.

Bagher Larijani (B)

Endocrinology and Metabolism Research Center Endocrinology and Metabolism Clinical Sciences Institute Tehran University of Medical Sciences Tehran Iran.

Mohamad Taghi Majnoon (MT)

Pediatric Group Children Medical Center Faculty of Medicine Tehran University of Medical Sciences Tehran Iran.

Farshad Farzadfar (F)

Non-Communicable Diseases Research Center Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.
Endocrinology and Metabolism Research Center Endocrinology and Metabolism Clinical Sciences Institute Tehran University of Medical Sciences Tehran Iran.

Ali H Mokdad (AH)

Institute for Health Metrics and Evaluation University of Washington Seattle WA.
Department of Health Metrics Sciences University of Washington Seattle WA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH